Structure for inhibitor I04.002: alpha-1-antichymotrypsin
 
| TERTIARY STRUCTURE DATA | ||||||||
|---|---|---|---|---|---|---|---|---|
| Comment | Resolution | PDB | PDBe | SCOP | CATH | PDBSum | Proteopedia | Reference |
| Homo sapiens | ||||||||
| Ala249Arg mutant; cleaved form | 2.10 Å | 1AS4 | 1AS4 | 1AS4 | 1AS4 | 1AS4 | 1AS4 | Lukacs et al., 1998 |
| alpha1-antichymotrypsin serpin in the delta conformation (partial loop insertion) | 2.27 Å | 1QMN | 1QMN | 1QMN | 1QMN | 1QMN | 1QMN | Gooptu et al., 2000 |
| Cleaved form | 2.70 Å | 2ACH | 2ACH | 2ACH | 2ACH | 2ACH | 2ACH | Baumann et al., 1991 |
| Ala347Arg mutant; cleaved form | 2.40 Å | 3CAA | 3CAA | 3CAA | 3CAA | 3CAA | 3CAA | Lukacs et al., 1996 |
| mature inhibitor | 2.70 Å | 3DLW | 3DLW | 3DLW | 3DLW | 3DLW | 3DLW | |
| Thr345Arg mutant; cleaved form | 2.90 Å | 4CAA | 4CAA | 4CAA | 4CAA | 4CAA | 4CAA | Lukacs et al., 1996 |
| crystal structure of alpha1-antichymotrypsin variant dbs-i1: a drug- binding serpin for doxycycline | 1.47 Å | 5OM2 | 5OM2 | 5OM2 | 5OM2 | 5OM2 | 5OM2 | |
| crystal structure of alpha1-antichymotrypsin variant dbs-i5: a mmp14- cleavable drug-binding serpin for doxycycline | 2.00 Å | 5OM3 | 5OM3 | 5OM3 | 5OM3 | 5OM3 | 5OM3 | |
| crystal structure of alpha1-antichymotrypsin variant dbs-i-allo1: an allosterically triggered drug-binding serpin for doxycycline | 1.60 Å | 5OM5 | 5OM5 | 5OM5 | 5OM5 | 5OM5 | 5OM5 | |
| crystal structure of alpha1-antichymotrypsin variant dbs-i-allo2: a mmp9-cleavable drug-binding serpin for doxycycline | 1.85 Å | 5OM6 | 5OM6 | 5OM6 | 5OM6 | 5OM6 | 5OM6 | |
| crystal structure of alpha1-antichymotrypsin variant dbs-ii: a drug- binding serpin for doxorubicin | 1.73 Å | 5OM7 | 5OM7 | 5OM7 | 5OM7 | 5OM7 | 5OM7 | |
| crystal form 2 of alpha1-antichymotrypsin variant dbs-ii-allo: an allosterically modulated drug-binding serpin for doxorubicin | 2.20 Å | 5OM8 | 5OM8 | 5OM8 | 5OM8 | 5OM8 | 5OM8 | |
| crystal form 1 of alpha1-antichymotrypsin variant dbs-ii-allo: an allosterically modulated drug-binding serpin for doxorubicin | 1.80 Å | 6FTP | 6FTP | 6FTP | 6FTP | 6FTP | 6FTP | |
| crystal structure of alpha1-antichymotrypsin variant newbg-0: a new binding globulin variant that is devoid of any cortisol-binding capabilities | 1.90 Å | 6HGD | 6HGD | 6HGD | 6HGD | 6HGD | 6HGD | |
| crystal structure of alpha1-antichymotrypsin variant newbg-i in the uncleaved s-conformation | 2.80 Å | 6HGE | 6HGE | 6HGE | 6HGE | 6HGE | 6HGE | |
| variant newbg-II; complex with cortisol | 1.65 Å | 6HGF | 6HGF | 6HGF | 6HGF | 6HGF | 6HGF | |
| variant newbg-III; complex with cortisol | 1.79 Å | 6HGG | 6HGG | 6HGG | 6HGG | 6HGG | 6HGG | |
| crystal structure of alpha1-antichymotrypsin variant newbg-iii: a new binding globulin without any bound ligand | 1.90 Å | 6HGH | 6HGH | 6HGH | 6HGH | 6HGH | 6HGH | |
| variant newbg-III; complex with corticosterone | 1.52 Å | 6HGI | 6HGI | 6HGI | 6HGI | 6HGI | 6HGI | |
| variant newbg-III; complex with aldosterone | 1.83 Å | 6HGJ | 6HGJ | 6HGJ | 6HGJ | 6HGJ | 6HGJ | |
| variant newbg-III; complex with progesterone | 1.86 Å | 6HGK | 6HGK | 6HGK | 6HGK | 6HGK | 6HGK | |
| variant newbg-III; complex with testosterone | 1.92 Å | 6HGL | 6HGL | 6HGL | 6HGL | 6HGL | 6HGL | |
| crystal structure of alpha1-antichymotrypsin variant newbg-iii-allo: an allosterically controlled new binding globulin with an unprecedentedly high ligand release efficacy | 1.37 Å | 6HGM | 6HGM | 6HGM | 6HGM | 6HGM | 6HGM | |
| crystal structure of alpha1-antichymotrypsin variant dbs-ii-allo-l55v:an allosterically controlled doxorubicin-binding serpin with an unprecedentedly high ligand release efficacy | 1.48 Å | 6HGN | 6HGN | 6HGN | 6HGN | 6HGN | 6HGN | |
